Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Summary of Benefits (2)
Bone mineral content increased in rhGH-treated patients, but it is not known if this change alters fracture risk and the strength of evidence is low. Percent predicted FEV1 is a good predictor of mortality risk and influences HRQoL reporting. However, moderate-strength evidence indicates that rhGH treatment did not improve this measure.
Keywords: BMC | bone mineral content | percent predicted FEV1 | fracture risk | mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.